Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C

Table 5 Univariate and multivariate analysis of factors contributing to SVR24 (telaprevir)

Factors	Univariate analysis		Multivariate analysis
	Odds ratio (95%CI)	P value	Odds ratio (95%CI)	P value
Age	1.012 (0.955-1.072)	0.689
Gender (female)	0.784 (0.262-2.342)	0.663
Body mass index (kg/m2)	1.074 (0.875-1.318)	0.495
Prior treatment response (non-NR)	3.850 (0.830-17.861)	0.085
Baseline HCV-RNA (log IU/mL)	1.264 (0.457-3.495)	0.652
Baseline ALT (IU/mL)	1.008 (0.998-1.017)	0.105
Baseline platelets (× 104/mm3)	1.017 (0.906-1.142)	0.775
Baseline hemoglobin (g/dL)	1.038 (0.736-1.464)	0.830
IL28B SNP (TT)	6.700 (1.826-24.584)	0.004	8.160 (1.593-41.804)	0.012
Initial dose of TVR (2250 mg/d)	2.069 (0.670-6.553)	0.204
TVR/BW (mg/kg per day)	0.938 (0.870-1.011)	0.093
RBV/BW (mg/kg per day)	0.811 (0.617-1.066)	0.133
PEG-IFN dose reduction (none)	2.134 (0.253-17.988)	0.486
TVR dose reduction (none)	1.020 (0.281-3.703)	0.976
RBV dose reduction (none)	1.548 (0.433-5.525)	0.501
Adherence of RBV (> 60%)	6.873 (1.784-26.474)	0.005	11.052 (1.160-105.273)	0.037
RVR (none)	0.88 (0.123-1.216)	0.104

HCV: Hepatitis C virus; ALT: Alanine aminotransferase; NR: Non-responder; IL28B SNP: Interleukin-28B single nucleotide polymorphism; TVR: Telaprevir; RVR: Rapid virological response; PEG-IFN: Pegylated interferon; BW: Bodyweight; RBV: Ribavirin.